A Comparison Between Etomidate and Methohexital for Anesthesia in ECT.

Area of Science:

• Anesthesiology
• Neurology
• Pharmacology

Background:

• Electroconvulsive therapy (ECT) requires safe and effective anesthetic agents.
• Methohexital is a common anesthetic for ECT, but alternatives are sought.
• Etomidate offers potential benefits but requires comparative evaluation.

Purpose of the Study:

• To compare the efficacy and safety of etomidate versus methohexital for anesthesia during ECT.
• To evaluate hemodynamic stability, recovery profiles, and patient comfort between the two agents.

Main Methods:

• Prospective, randomized, open-label, within-patient crossover study.
• Twenty patients received both methohexital (1.0 mg/kg) and etomidate (0.3 mg/kg) for ECT.
• Hemodynamics, induction time, seizure duration, wakeup time, and recovery room stay were monitored.

Main Results:

• No significant differences in hemodynamics or cardiac rhythms between etomidate and methohexital.
• Etomidate resulted in a 24% longer mean wakeup time compared to methohexital.
• Increased incidence of pain on injection was noted with etomidate; no differences in recovery stay or seizure duration.

Conclusions:

• Etomidate is a hemodynamically stable anesthetic for ECT, comparable to methohexital.
• Longer wakeup time and injection pain are potential drawbacks of etomidate.
• Etomidate presents an acceptable alternative to methohexital, especially in cases where barbiturates are contraindicated.